• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors

    5/18/21 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email

    PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania's (LSPA) Board of Directors, effective May 6, 2021.

    Harmony Biosciences logo (PRNewsfoto/Harmony Biosciences)

    John Jacobs' election to the board is accompanied by other leaders representing the breadth, diversity and geographic reach of LSPA across the medical device, diagnostic, biopharmaceutical, and research communities, bringing important expertise, insights, and partnerships that will help enhance the association's effectiveness. He will provide insight and guidance to the association given his deep experience of almost three decades in the pharmaceutical and life sciences industry.

    "The appointment of John to the Board of Directors is a testament to the work done by Harmony under his leadership to help the local patient community and raise the profile of life science companies in the region. We are grateful that John has agreed to serve on LSPA's Board of Directors and we look forward to working with him to advance the Association's initiatives," said Christopher P. Molineaux, President and CEO of Life Sciences Pennsylvania. 

    "Life Sciences Pennsylvania plays a critical and inspiring role in supporting and elevating the life sciences industry in Pennsylvania," Jacobs said. "I am honored to be joining the Board and helping to continue to make Pennsylvania a global life sciences leader."

    About Harmony Biosciences 

    Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

    About Life Sciences Pennsylvania

    Life Sciences Pennsylvania (LSPA) is the trade association for the Commonwealth's life sciences community. Founded in 1989, LSPA works to ensure Pennsylvania has a business and public policy climate that unites and incentivizes all facets of the state's diverse life sciences economy.

    LSPA represents biotechnology, medical device, diagnostic, pharmaceutical, research, and investment entities, along with myriad service providers who support the industry. Together, we unify Pennsylvania's innovators to make the Commonwealth a global life sciences leader.

    Harmony Biosciences Media Contact: 

    Nancy Leone 

    215-891-6046 

    nleone@harmonybiosciences.com 

    Harmony Biosciences Investor Contact: 

    Lisa Caperelli 

    484-539-9736 

    lcaperelli@harmonybiosciences.com 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/john-c-jacobs-president-and-ceo-of-harmony-biosciences-joins-life-sciences-pennsylvania-board-of-directors-301293009.html

    SOURCE Harmony Biosciences

    Get the next $HRMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    2/23/2026Buy → Hold
    Deutsche Bank
    2/23/2026Buy → Hold
    Truist
    2/11/2026$46.00Neutral
    UBS
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    More analyst ratings

    $HRMY
    SEC Filings

    View All

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    6/4/26 4:23:23 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    5/14/26 4:31:08 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    5/8/26 4:08:24 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Harmony Biosciences downgraded by Deutsche Bank

    Deutsche Bank downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:47 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences downgraded by Truist

    Truist downgraded Harmony Biosciences from Buy to Hold

    2/23/26 8:31:36 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Harmony Biosciences with a new price target

    UBS resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $46.00

    2/11/26 7:39:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences to Participate in Upcoming Investor Conferences

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for

    5/27/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

    WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026 Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timefra

    5/7/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Germano Geno J

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/18/26 9:51:38 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Germano Geno J

    3 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/18/26 9:50:42 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Szyper Linda M

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    5/18/26 4:19:48 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

    WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026 Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timefra

    5/7/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Bioscien

    4/23/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

    WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications Potential Best-In-Class Orexin-2 Agonist (BP1.15205) Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026 Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced ear

    2/24/26 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

    COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and privately held companies, guiding them through key growth inflection points. With his experience as a sell-side analyst, investor and biotech CFO, he brings

    4/14/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

    Appointments support Harmony's next phase of growth and long‑term value creation Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight across the business during a period of continued growth and operational evolution. He brings more than three decades of experience building and leading biotechn

    4/2/26 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care